Portal:CPTAC/Hallmark/Therapeutics
From WikiPathways
(Difference between revisions)
(New page: *Pathway:WP3672 *Pathway:WP3640 *Pathway:WP3614 *Pathway:WP3617 *Pathway:WP3879 *Pathway:WP1601) |
(added pw titles) |
||
| Line 1: | Line 1: | ||
| - | *[[Pathway:WP3672]] | + | *[[Pathway:WP3672]] LncRNA-mediated mechanisms of therapeutic resistance |
| - | *[[Pathway:WP3640]] | + | *[[Pathway:WP3640]] Imatinib and Chronic Myeloid Leukemia |
| - | *[[Pathway:WP3614]] | + | *[[Pathway:WP3614]] Photodynamic therapy-induced HIF-1 survival signaling |
| - | *[[Pathway:WP3617]] | + | *[[Pathway:WP3617]] Photodynamic therapy-induced NF-kB survival signaling |
| - | *[[Pathway:WP3879]] | + | *[[Pathway:WP3879]] 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression |
| - | *[[Pathway:WP1601]] | + | *[[Pathway:WP1601]] Fluoropyrimidine Activity |
Revision as of 03:13, 6 October 2017
- Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
- Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
- Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
- Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
- Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
- Pathway:WP1601 Fluoropyrimidine Activity
